NFIB is a potential target for estrogen receptor‐negative breast cancers
- 8 August 2011
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 5 (6) , 538-544
Abstract
Background: The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested.Methods: We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients.Results: By using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over‐expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway.Conclusions: Our results show a potential role of NFIB as a novel target in ER negative breast cancers.Keywords
This publication has 25 references indexed in Scilit:
- Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancerBreast Cancer Research, 2011
- Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast CancerPLOS ONE, 2010
- Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic ImplicationsCancer Research and Treatment, 2010
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neckProceedings of the National Academy of Sciences, 2009
- miR-21 as a key regulator of oncogenic processesBiochemical Society Transactions, 2009
- Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990sEuropean Journal of Cancer, 2008
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast Cancer Research, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005